• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    6/3/25 1:48:23 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    424B3 1 form424b3.htm 424B3

     

    Filed Pursuant to Rule 424(b)(3)

    Registration No. 333-280414

     

    PROSPECTUS SUPPLEMENT NO. 2

    (To Prospectus dated May 7, 2025)

     

     

    Tevogen Bio Holdings Inc.

     

    This prospectus supplement updates and supplements the prospectus, dated May 7, 2025 (as supplemented to date, the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280414), as amended. This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2025 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this prospectus supplement.

     

    This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

     

    Our common stock, par value $0.0001 per share (“Common Stock”), and public warrants to purchase Common Stock (“Warrants”) are listed on The Nasdaq Stock Market LLC under the symbols “TVGN” and “TVGNW,” respectively. On June 2, 2025, the closing price of our Common Stock was $1.29 and the closing price for our Warrants was $0.0585.

     

    We are an “emerging growth company” and “smaller reporting company” for purposes of federal securities laws and are subject to reduced public company reporting requirements. Accordingly, the information in the Prospectus and this prospectus supplement may not be comparable to information provided by companies that are not emerging growth companies or smaller reporting companies.

     

    Our business and investment in our Common Stock and Warrants involve significant risks. These risks are described in the section titled “Risk Factors” beginning on page 8 of the Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

     

    The date of this prospectus supplement is June 3, 2025.

     

     
     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 30, 2025

     

     

     

    Tevogen Bio Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41002   98-1597194

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    15 Independence Boulevard, Suite #210

    Warren, NJ

      07059
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (877) 838-6436

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   TVGN   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one share of Common Stock for $11.50 per share  

    TVGNW

      The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On May 30, 2025, Tevogen Bio Inc. (“Tevogen Bio”), a wholly owned subsidiary of Tevogen Bio Holdings Inc. (the “Company”), entered into Amendment No. 1 (the “Amendment”) to that certain Lease Agreement, dated February 1, 2022, between Tevogen Bio and Mitsui Sumitomo Insurance Company of America (as amended, the “Lease Agreement”). The Lease Agreement relates to the Company’s principal executive offices located at 15 Independence Boulevard, Warren, New Jersey. The Amendment doubles the amount of leased space and extends the term of the Lease Agreement until February 2033. The Company’s annual payment under the Lease Agreement will be approximately $330,000.

     

    The Company expects to relocate employees at its Philadelphia, Pennsylvania research and development center to the premises leased under the Lease Agreement following the June 2025 expiration of the research and development center lease.

     

    The foregoing description is qualified by reference to the full text of the Amendment, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit  

    Description

    10.1   Amendment No. 1 to the Lease Agreement, dated as of May 30, 2025, between Mitsui Sumitomo Insurance Company of America and Tevogen Bio Inc.
    104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Tevogen Bio Holdings Inc.
         
    Date: June 3, 2025 By: /s/ Ryan Saadi
      Name: Ryan Saadi
      Title: Chief Executive Officer

     

    3

     

     

    Exhibit 10.1

     

    AMENDMENT No. 1

     

    to the

     

    LEASE AGREEMENT

     

    (Hereinafter referred to as the “Lease”)

     

    Between

     

    MITSUI SUMITOMO INSURANCE COMPANY OF AMERICA

     

    With Offices At

     

    15 Independence Boulevard

    Warren, New Jersey 07059

     

    (Hereinafter referred to as “Landlord”)

     

    And

     

    Tevogen Bio Inc.

     

    With Offices At

     

    15 Independence Boulevard

    Warren, New Jersey 07059

     

    (Hereinafter referred to as “Tenant”)

     

     

     

     

    WHEREAS, Landlord and Tenant entered into that certain Lease Agreement, dated as of February 1, 2022 (the “Original Lease”), pursuant to which the Landlord leased to Tenant, and Tenant leased from Landlord, approximately 6,708 rentable square feet (“RSF”) of space on the 4th floor of that certain office building located at 15 Independence Boulevard, Warren, New Jersey (the “Building”), as more particularly described in the Lease; and

     

    WHEREAS, Tenant desires to relocate to different premises within the Building and extend the lease term, and Landlord is amenable to same, subject to the terms and conditions set forth in this First Amendment;

     

    NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, Landlord and Tenant hereby agree as follows:

     

    1. Defined Terms. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Original Lease.

     

    2. Relocation Premises. Effective as of June 1, 2025 (the “Relocation Commencement Date”), Tenant shall relocate to and lease approximately 13,242 RSF on the 2nd floor (the “Relocated Premises”), as more particularly shown on Exhibit A attached hereto and made a part hereof. The lease of the existing 4th floor premises shall be deemed terminated and surrendered as of the Relocation Commencement Date, and Tenant shall have no further rights or obligations with respect thereto, except for those that expressly survive expiration or termination under the Original Lease. Tenant shall have access to the Relocated Premises beginning on May 27, 2025 for the purpose of installing FF&E and Tenant’s IT needs.

     

    3. Lease Term. The term of the Lease shall be extended for seven (7) years from the current lease expiration date of February 28, 2026, resulting in a new expiration date of February 28, 2033 (the “Extended Term”).

     

    5. Base Rent. Effective as of the Relocation Commencement Date, the Base Rent for the Relocation Premises shall be $24.75 per RSF, plus Tenant Electric, flat for the Term.

     

    6. Base Rent Abatement. Tenant shall be entitled to one (1) month of Base Rent abatement applicable to the Relocation Premises only.

     

    7. Landlord’s Work. Landlord shall provide new carpet and paint throughout the Relocation Premises, promptly after the full execution of this First Amendment.

     

    8. Base Year. The Base Year shall remain unchanged from the Original Lease.

     

     

     

     

    9. Broker. Tenant represents to Landlord that in connection with this First Amendment: (a) Tenant has not employed or dealt with any broker, agent, or finder, other than Newmark, and (b) no other broker, agent or finder is entitled to any commission or other payment. Tenant shall indemnify, defend, and hold harmless Landlord and its partners, members, shareholders, officers, directors, and agents, from and against any claims, demands, liabilities, causes of action, suits, judgments, damages and expenses (including reasonable attorneys’ fees) arising out of or relating to a claim by any broker, agent or finder, other than Newmark, claiming to have been engaged by Tenant.

     

    10. Electronic Delivery. The parties agree that this First Amendment may be transmitted between them by email or via an electronic signature platform such as DocuSign, and intend that scanned signatures (such as, without limitation, scanned signatures in .pdf format) constitute original signatures, and that a scanned agreement containing the signatures (original or scanned) of all the parties is binding on the parties.

     

    IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed by their respective representatives, each of whom warrants they have the authority to sign this First Amendment and bind their employer.

     

    MITSUI SUMITOMO INSURANCE COMPANY OF AMERICA
           
    By: /s/ Jeff Elefant   Mitsui Sumitomo Marine Management(USA), Inc.as Manager for and on behalf of Mitsui Sumitomo Insurance Company of America, a New York corporation
         
    Typed Name: Jeff Elefant  
         
    Title: VP Real Estate & Facilities    
           
    Date: 5/30/2025    
           
    TEVOGEN BIO INC.    
           
    By: /s/ Kirti Desai    
           
    Typed Name: Kirti Desai    
           
    Title: Chief Financial Officer    
           
    Date: 5/16/2025    

     

     

     

    Get the next $TVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

      WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs. Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation

      5/30/25 11:01:18 AM ET
      $MSFT
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

      WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population.

      5/23/25 3:49:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

      WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting, Tevogen intends to provide information on: Portfolio Assets: The Company will provide an update on its robust portfolio assets of Tevogen Bio Oncology, Tevogen Bio Specialty Care and

      5/22/25 1:21:42 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    SEC Filings

    See more
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/3/25 1:48:23 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/3/25 1:46:13 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/14/25 5:27:46 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/14/24 5:29:01 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/12/24 4:28:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

      SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      3/4/24 4:24:14 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Financials

    Live finance-specific insights

    See more
    • Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

      WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

      2/14/25 1:16:54 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

      WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

      8/22/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

      WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com

      8/15/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/29/25 8:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/14/25 1:53:50 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

      WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a

      3/26/25 3:12:23 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Tevogen Bio with a new price target

      D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

      3/4/25 8:26:08 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Flomenberg Neal sold $253,935 worth of shares (232,968 units at $1.09), decreasing direct ownership by 6% to 3,595,608 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/14/25 9:02:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $231,734 worth of shares (211,909 units at $1.09), decreasing direct ownership by 5% to 3,828,576 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/11/25 8:52:08 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $250,006 worth of shares (213,817 units at $1.17), decreasing direct ownership by 5% to 4,040,485 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/6/25 9:41:49 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care